Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity

Fig. 1

Synergistic BCMA interactions with the cilta-cel tandem of nanobodies. a Schematic diagrams of BCMA and CAR constructs used in this study. ECD extracellular domain, TM transmembrane region, ICD intracellular domain, LTR long terminal repeat, SP signal peptide, Nb1, Nb2, and NbT, nanobody 1, 2, and tandem. Regarding the CAR constructs, the SP, hinge, and TM domains are derived from human CD8α. b, c Characteristics of BCMA–nanobody binding assayed by surface plasmon resonance (SPR). SPR sensorgrams of nanobodies as the analytes (concentration [nM] indicated) over immobilized BCMAECD-His (b) or BCMAECD-Fc (c) as the ligands. Binding models (Langmuir or heterogeneous ligand) used for fitting (black overlay) are denoted above and the derived affinities and kinetics are shown below each chart

Back to article page